Landscapes / Companies
Furthest along
21 approved
13 in Phase 3
Drugs
67
in active trials · 287 in all
Trials
138 active
679 since 2021
Drugs67
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Approved | 25 Nov 2026soonPhase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 25 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia (wAIHA) and 8 more | ||||
| Open drug page | |||||
— |
Approved in the EU | 26 Nov 2026soonPhase 4 trial completes | |||
| Next date | 26 Nov 2026 · Phase 4 trial completes | ||||
| Also tested for | COVID-19 | ||||
| Open drug page | |||||
— |
Approved | 28 Nov 2026soonPhase 3 trial completes | |||
| Next date | 28 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Yellow Fever, Yellow Fever Immunization | ||||
| Open drug page | |||||
Efanesoctocog alfanot checked |
— |
On the market | 15 Jan 2027Phase 3 trial completes | ||
| Next date | 15 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Hemophilia A, Factor VIII Deficiency | ||||
| Open drug page | |||||
Monoclonal antibody |
Regeneron |
Approved | 7 Feb 2027Phase 4 trial completes | ||
| How it works | An antibody | ||||
| Next date | 7 Feb 2027 · Phase 4 trial completes | ||||
| Also tested for | Asthma, Dermatitis Atopic and 14 more | ||||
| Open drug page | |||||
Small interfering RNA |
Approved | 25 Mar 2027Phase 3 trial completes | |||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 25 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Hemophilia, Hemophilia A | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 1 Apr 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Plasma Cell Myeloma, Plasma Cell Myeloma Refractory and 2 more | ||||
| Open drug page | |||||
— |
Approved in the EU | 17 May 2027Phase 3 trial completes | |||
| Next date | 17 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Pneumococcal Immunization | ||||
| Open drug page | |||||
— |
Approved | 17 May 2027Phase 1/2 trial completes | |||
| Next date | 17 May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Meningococcal Immunisation, Meningococcal Immunization and 1 more | ||||
| Open drug page | |||||
Histamine-1 receptor antagonist |
Approved | 2 Jun 2027Phase 3 trial completes | |||
| Next date | 2 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Pruritus | ||||
| Open drug page | |||||
Hydrolytic lysosomal glycogen-specific enzyme |
Approved | 30 Jun 2027Phase 4 trial completes | |||
| Next date | 30 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Glycogen Storage Disease Type II, Glycogen Storage Disease Type II-Pompe's Disease and 1 more | ||||
| Open drug page | |||||
Belumosudilnot checked |
— |
Approved | 30 Aug 2027Phase 4 trial completes | ||
| Next date | 30 Aug 2027 · Phase 4 trial completes | ||||
| Also tested for | Chronic Graft Versus Host Disease, Plasma Cell Myeloma Refractory and 1 more | ||||
| Open drug page | |||||
— |
Hanmi Pharmaceutical Company Limited |
Approved in South Korea | Nov 2027Phase 3 trial completes | ||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Type 2 diabetes | ||||
| Open drug page | |||||
Interleukin-6 receptor antagonist |
Approved | 1 Mar 2028Phase 2 trial completes | |||
| How it works | Blocks interleukin-6 | ||||
| Next date | 1 Mar 2028 · Phase 2 trial completes | ||||
| Also tested for | Juvenile Idiopathic Arthritis, Polymyalgia Rheumatica and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 6 Mar 2028Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 6 Mar 2028 · Phase 2 trial completes | ||||
| Also tested for | Type 1 Diabetes Mellitus | ||||
| Open drug page | |||||
BTK inhibitor (brain-penetrant) |
Approved in the EU | 30 Apr 2029Phase 3 trial completes | |||
| Next date | 30 Apr 2029 · Phase 3 trial completes | ||||
| Also tested for | Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis and 1 more | ||||
| Open drug page | |||||
Imiglucerasenot checked |
Hydrolytic lysosomal glucocerebroside-specific enzyme |
Approved | 14 Jan 2030Phase 3 trial completes | ||
| Next date | 14 Jan 2030 · Phase 3 trial completes | ||||
| Also tested for | Gaucher's Disease Type III, Gaucher Disease Type 1 and 1 more | ||||
| Open drug page | |||||
Hydrolytic lysosomal neutral glycosphingolipid-specific enzyme |
Approved | — | |||
| Also tested for | Fabry Disease | ||||
| Open drug page | |||||
Hydrolytic lysosomal glycogen-specific enzyme |
Approved | — | |||
| Also tested for | Glycogen Storage Disease Type II-Pompe's Disease | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Type 2 Diabetes (T2D) | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings
All on SEC.govNo filings loaded yet.
About
- No active trial
- 220 other drugs
- Registry names
- 11 names in ClinicalTrials.gov Sanofi
Sanofi Pasteur, a Sanofi Company
Genzyme, a Sanofi Company
Bioverativ, a Sanofi company
Kadmon, a Sanofi Company
Principia Biopharma, a Sanofi Company
Kymab Limited
Provention Bio, a Sanofi Company
Opella Healthcare Group SAS, a Sanofi Company
Ablynx, a Sanofi company
Synthorx, Inc, a Sanofi company - Sources
- ClinicalTrials.gov updated 18 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021